Discover 503 paid clinical trials in Louisville, Kentucky. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 503
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
for
Chronic Rhinosinusitis Without Nasal Polyps
Location: Louisville KY, Springfield IL, Columbia MO,
Sponsor: Optinose US Inc.
Sex: All
Age: 12 - 17
Code: NCT06850805
Phase 3, Recruiting
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
Get alerts for new trials in your area by subscribing now
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
for
Coronary Artery Disease
Location: Louisville KY, Lexington KY, Carmel IN, Nashville TN,
Sponsor: Weill Medical College of Cornell University
Sex: All
Age: 18+
Code: NCT06399692
Phase 3, Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Louisville KY, Indianapolis IN, Fairfield OH,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07365241
Phase 3, Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
for
Heart Failure - NYHA II - IV
Location: Louisville KY, Indianapolis IN, Nashville TN,
Sponsor: Boston Scientific Corporation
Sex: All
Age: 18+
Code: NCT07069738
Recruiting
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
Location: New Albany IN, Lexington KY, Miamisburg OH, Columbus OH,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT06072482
Phase 4, Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Location: Louisville KY, Nashville TN, Columbus OH, Chicago IL,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT05735184
Phase 1, Recruiting
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
for
Indolent B-Cell Non-Hodgkin Lymphoma
Location: Louisville KY
Sponsor: BioInvent International AB
Sex: All
Age: 18+
Code: NCT03571568
Phase 1, Phase 2, Recruiting
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
for
Multiple Myeloma (MM)
Location: Louisville KY, Atlanta GA, Grand Rapids MI, Durham NC,
Sponsor: C4 Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07280013
Phase 1, Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for
Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Louisville KY, Lexington KY, Indianapolis IN,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06890338
Phase 2, Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
for
Systemic Lupus Erythematosus (With and Without Nephritis),
Location: Louisville KY, Chicago IL, Greenville SC, Charlotte NC,
Sponsor: Allogene Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT07085104
Phase 1, Recruiting
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Louisville KY, Hilliard OH, Chicago IL, Detroit MI,
Sponsor: Regeneron Pharmaceuticals
Sex: Female
Age: 18+
Code: NCT06787612
Phase 2, Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All
Age: 18+
Code: NCT06297226
Phase 2, Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)